hTERT expression and prognosis in B-chronic lymphocytic leukemia

Página do item simplificado
dc.contributor.authorTchirkov, A.
dc.contributor.authorChaleteix, C.
dc.contributor.authorMagnac, C.
dc.contributor.authorVasconcelos, Yuri [UNIFESP]
dc.contributor.authorDavi, F.
dc.contributor.authorMichel, A.
dc.contributor.authorKwiatkowski, F.
dc.contributor.authorTournilhac, O.
dc.contributor.authorDighiero, G.
dc.contributor.authorTravade, P.
dc.contributor.institutionCtr Jean Perrin
dc.contributor.institutionCHU
dc.contributor.institutionInst Pasteur
dc.contributor.institutionHop La Pitie Salpetriere
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T12:37:23Z
dc.date.available2016-01-24T12:37:23Z
dc.date.issued2004-10-01
dc.description.abstractBackground: in B-chronic lymphocytic leukemia (B-CLL), there is a need for molecular markers to predict the evolution of this heterogeneous disease in individual patients. the level of expression of the human telomerase reverse transcriptase (hTERT) gene has been associated with disease aggressiveness in human cancers. the purpose of the present study was to examine the prognostic significance of hTERT expression in B-CLL.Patients and methods: We used real-time reverse transcription-PCR to quantitate the amount of hTERT transcripts in mononuclear blood cells from 90 B-CLL patients. in addition, samples were analyzed for somatic mutations in the immunoglobulin V (IgV) genes.Results: the expression of hTERT gene was detected in 59% of patients. the level of expression increased with advancing B-CLL stage (P = 0.0064). Patients expressing hTERT showed significantly shorter survival than hTERT-negative patients (P=0.000034), irrespective of the disease stage. On average, the level hTERT mRNA expression was seven-fold higher in the poor-prognosis B-CLL group with unmutated IgV than in the Ig-mutated group (p< 10(-7)). the level of hTERT expression discriminated the Ig-unmutated from Ig-mutated B-CLL in 89% of cases.Conclusion: Our data indicate that hTERT expression in B-CLL may serve as a molecular prognostic marker.en
dc.description.affiliationCtr Jean Perrin, Dept Radiotherapie, F-63011 Clermont Ferrand 1, France
dc.description.affiliationCtr Jean Perrin, Serv Stat & Commun Med, F-63011 Clermont Ferrand, France
dc.description.affiliationCHU, Serv Hematol Clin, Clermont Ferrand, France
dc.description.affiliationInst Pasteur, Unite Immunohematol & Immunopathol, Paris, France
dc.description.affiliationHop La Pitie Salpetriere, Dept Hematol, Paris, France
dc.description.affiliationUniversidade Federal de São Paulo, Div Hematol, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Div Hematol, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent1476-1480
dc.identifierhttp://dx.doi.org/10.1093/annonc/mdh389
dc.identifier.citationAnnals of Oncology. Oxford: Oxford Univ Press, v. 15, n. 10, p. 1476-1480, 2004.
dc.identifier.doi10.1093/annonc/mdh389
dc.identifier.issn0923-7534
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/27946
dc.identifier.wosWOS:000224405200006
dc.language.isoeng
dc.publisherOxford Univ Press
dc.relation.ispartofAnnals of Oncology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.licensehttp://www.oxfordjournals.org/access_purchase/self-archiving_policyb.html
dc.subjectB-CLLen
dc.subjecthTERTen
dc.subjectprognosisen
dc.subjectreal-time reverse transcription-PCRen
dc.titlehTERT expression and prognosis in B-chronic lymphocytic leukemiaen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
Em verificação - Geral